EX-99.2

Exhibit 99.2

SCHERING-PLOUGH CORPORATION
STATEMENTS OF CONSOLIDATED OPERATIONS
(Dollars in Millions, except EPS)
(Unaudited)


	2007												2006
	1st			2nd			3rd	4th	6			Full	1st			2nd			3rd			4th			6			Full			2nd Qtr			6 Mos.
	Qtr.			Qtr.			Qtr.	Qtr.	Mos.			Year	Qtr.			Qtr.			Qtr.			Qtr.			Mos.			Year			vs			vs
	$			$			$	$	$			$	$			$			$			$			$			$			2nd Qtr			6 Mos.

Net sales		2,975			3,178					6,153				2,551			2,818			2,574			2,650			5,369			10,594			13	%		15	%

Cost of sales 1/		937			977					1,913				893			1,004			885			915			1,897			3,697			(3	%)		1	%

Gross profit		2,038			2,201					4,240				1,658			1,814			1,689			1,735			3,472			6,897			21	%		22	%
Selling, general and administrative		1,213			1,358					2,572				1,086			1,224			1,158			1,250			2,310			4,718			11	%		11	%
Research and development 2/		707			696					1,403				481			539			536			631			1,020			2,188			29	%		38	%
Other income, net 3/		(48	)		(16	)				(62	)			(34	)		(19	)		(37	)		(46	)		(52	)		(135	)		(16	%)		19	%
Special and acquisition related charges 4/		1			11					12				—			80			10			12			80			102			*			*
Equity income from cholesterol joint venture		(487	)		(490	)				(978	)			(311	)		(355	)		(390	)		(403	)		(666	)		(1,459	)		38	%		47	%

Income before income taxes		652			642					1,293				436			345			412			291			780			1,483			86	%		66	%

Income tax expense 4/		87			103					190				86			86			103			87			172			362			20	%		10	%

Net income before cumulative effect of a change in accounting principle		565			539					1,103				350			259			309			204			608			1,121			108	%		81	%

Cumulative effect of a change in accounting principle, net of tax		—			—					—				(22	)		—			—			—			(22	)		(22	)		*			*


Net income		565			539					1,103				372			259			309			204			630			1,143			108	%		75	%


Preferred stock dividends		22			22					43				22			22			22			22			43			86			*			*

Net income available to common shareholders		543			517					1,060				350			237			287			182			587			1,057			118	%		80	%


Diluted earnings per common share:
Earnings available to common shareholders before cumulative effect of a change in accounting principle 6/		0.36			0.34					0.70				0.22			0.16			0.19			0.12			0.38			0.69
Cumulative effect of a change in accounting principle, net of tax		—			—					—				0.02			—			—			—			0.02			0.02

Diluted earnings per common share 6/		0.36			0.34					0.70				0.24			0.16			0.19			0.12			0.40			0.71

Avg. shares outstanding- diluted		1,571			1,587					1,579				1,486			1,489			1,492			1,497			1,487			1,491
Actual shares outstanding		1,489			1,496					1,496				1,481			1,481			1,483			1,487			1,481			1,487




Ratios to net sales
Net sales		100.0	%		100.0	%				100.0	%			100.0	%		100.0	%		100.0	%		100.0	%		100.0	%		100.0	%
Cost of sales		31.5	%		30.7	%				31.1	%			35.0	%		35.6	%		34.4	%		34.5	%		35.3	%		34.9	%
Gross margin		68.5	%		69.3	%				68.9	%			65.0	%		64.4	%		65.6	%		65.5	%		64.7	%		65.1	%
Selling, general and administrative		40.8	%		42.7	%				41.8	%			42.6	%		43.4	%		45.0	%		47.2	%		43.0	%		44.5	%
Research and development		23.8	%		21.9	%				22.8	%			18.8	%		19.1	%		20.8	%		23.8	%		19.0	%		20.6	%
Income before income taxes		21.9	%		20.2	%				21.0	%			17.1	%		12.2	%		16.0	%		11.0	%		15.0	%		14.0	%
Net income		19.0	%		17.0	%				17.9	%			14.6	%		9.2	%		12.0	%		7.7	%		11.8	%		10.8	%


*		Not a meaningful percentage

		Note: The Company incurs substantial costs, such as selling, general and administrative costs, that are not reflected in the “Equity income from cholesterol joint venture” and are borne by the overall cost structure of Schering-Plough.

1/		Included in cost of sales for the three and six months ended June 30, 2006 is $58 million of inventory write-off’s and accelerated depreciation related to the manufacturing changes announced June 1, 2006. Cost of sales for the twelve months ended December 31, 2006 included $146 million of inventory write-offs, accelerated depreciation and other charges related to the manufacturing changes.

2/		Research and development for the three months ended June 30, 2007 includes $60 million related to an upfront payment made for licensing of a product. Research and development for the six months ended June 30, 2007 includes $156 million related to upfront payments made for licensing of products. Included in research and development for the twelve months ended December 31, 2006 is a $15 million payment for licensing of a product.

3/		Included in other income, net for the three and six months ended June 30, 2007 is $35 million and $31 million, respectively, related to a mark-to-market loss on a Euro denominated currency option related to the planned acquisition of Organon BioSciences.

4/		For the three and six months ended June 30, 2007, special and acquisition related charges comprised of integration planning activities related to Organon BioSciences in the amount of $11 million and $12 million, respectively.

		Special and acquisition related charges of $102 million for the twelve months ended December 31, 2006 include severance and fixed asset write-offs related to the manufacturing changes.

5/		Tax expense for all periods presented primarily relates to foreign tax expense as the Company did not recognize the benefit of U.S. tax operating losses.

6/		Diluted earnings per common share for the three month period ended June 30, 2007 is calculated based on net income of $539 million and average diluted shares outstanding of 1,587. Diluted earnings per common share for the six month period ended June 30, 2007 is calculated based on net income of $1.103 billion and average diluted shares outstanding of 1,579. Diluted earnings per common share for the three month period ended March 31, 2007 is calculated based on net income of $565 million and average diluted shares outstanding of 1,571. The increase in average diluted shares outstanding for the three and six month period ended June 30, 2007 and three month period ended March 31, 2007 are due to the preferred shares being dilutive under accounting rules. The preferred shares were not dilutive in 2006.

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 1

SCHERING-PLOUGH CORPORATION
ANALYSIS OF NET SALES AND ADJUSTED NET SALES
(Dollars in Millions)


	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.

*Cholesterol Joint Venture:*		*1,150*		*1,248*				*2,397*			*778*		*958*		*1,010*		*1,082*		*1,736*		*3,829*		30	%		38	%
U.S.		897		958				1,854			634		784		820		852		1,419		3,091		22	%		31	%
International		253		290				543			144		174		190		230		317		738		68	%		71	%


*50% of Cholesterol Joint Venture:*		575		624				1,199			389		479		505		541		868		1,915		30	%		38	%


*Prescription Pharma:*		*2,398*		*2,520*				*4,918*			*2,032*		*2,230*		*2,087*		*2,211*		*4,263*		*8,561*		13	%		15	%
U.S.		802		771				1,573			656		718		733		800		1,375		2,908		7	%		14	%
International		1,596		1,749				3,345			1,376		1,512		1,354		1,411		2,888		5,653		16	%		16	%


*Consumer Health Care*		*345*		*394*				*739*			*311*		*349*		*259*		*205*		*659*		*1,123*		13	%		12	%


*Animal Health:*		*232*		*264*				*496*			*208*		*239*		*228*		*234*		*447*		*910*		10	%		11	%
U.S.		58		58				116			57		62		72		50		118		240		(6	%)		(2	%)
International		174		206				380			151		177		156		184		329		670		16	%		15	%


*Consolidated GAAP Net Sales:*		*2,975*		*3,178*				*6,153*			*2,551*		*2,818*		*2,574*		*2,650*		*5,369*		*10,594*		13	%		15	%

U.S.		1,179		1,195				2,374			999		1,103		1,047		1,043		2,102		4,192		8	%		13	%
International		1,796		1,983				3,779			1,552		1,715		1,527		1,607		3,267		6,402		16	%		16	%


*Adjusted Net Sales:*		*3,550*		*3,802*				*7,352*			*2,940*		*3,297*		*3,079*		*3,191*		*6,237*		*12,509*		15	%		18	%

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 2

SCHERING-PLOUGH CORPORATION
CHOLESTEROL FRANCHISE NET SALES
(Dollars in Millions)


	2007											2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.

*Global Zetia: 1/*		*544*		*605*				*1,149*			*415*		*474*		*501*		*535*		*889*		*1,925*		28	%		29	%

U.S.		408		424				832			315		363		389		405		679		1,472		17	%		23	%
International		136		181				317			100		111		112		130		210		453		63	%		51	%

*Global Vytorin: 1/*		*616*		*683*				*1,299*			*371*		*491*		*517*		*554*		*862*		*1,933*		39	%		51	%
U.S.		489		534				1,022			319		421		431		448		740		1,619		27	%		38	%
International		127		149				277			52		70		86		106		122		314		114	%		127	%

*Global Cholesterol: 1/*		*1,160*		*1,288*				*2,448*			*786*		*965*		*1,018*		*1,089*		*1,751*		*3,858*		34	%		40	%
U.S.		897		958				1,854			634		784		820		852		1,419		3,091		22	%		31	%
International		263		330				594			152		181		198		237		332		767		83	%		79	%


1/		Substantially all sales of cholesterol products are not included in Schering-Plough’s net sales. Global franchise sales include sales under the Merck/Schering-Plough partnership, plus any sales that are not part of the partnership, such as Schering-Plough sales of cholesterol products in Latin America and Japan. In Japan, Schering-Plough co-markets Zetia with Bayer HealthCare. Zetia was launched in Japan in June 2007. In the second quarter of 2007 and 2006, sales in non-joint venture territories of the cholesterol franchise totaled $40 million and $7 million, respectively. For the first six months of 2007 and 2006, sales in non-joint venture territories of the cholesterol franchise totaled $51 million and $14 million, respectively.

The results of the operation of the joint venture are reflected in equity income. As a result, Schering-Plough’s gross margin and ratios of selling, general and administrative expenses and R&D expenses as a percentage of sales do not reflect the benefit of the impact of the cholesterol joint venture’s operating results.

Schering-Plough utilizes the equity method of accounting for the joint venture. The cholesterol agreements provide for the sharing of operating income based upon percentages that vary by product, sales level and country. In the U.S. market, Schering-Plough receives a greater share of profits on the first $300 million of annual ZETIA sales. Above $300 million of annual ZETIA sales, the companies share profits equally. Schering-Plough’s allocation of joint venture income is increased by milestones earned. Further, either partner’s share of the joint venture’s operating income is subject to a reduction if the partner fails to perform a specified minimum number of physician details in a particular country. The partners agree annually to the minimum number of physician details by country.

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 3

SCHERING-PLOUGH CORPORATION
PRESCRIPTION PHARMACEUTICAL SALES — KEY PRODUCT NET SALES
(Dollars in Millions)


	Global Prescription Pharma							U.S.							International
	2007		2006					2007		2006					2007		2006
	2nd		2nd		2nd Qtr			2nd		2nd		2nd Qtr			2nd		2nd		2nd Qtr
	Qtr.		Qtr.		vs			Qtr.		Qtr.		vs			Qtr.		Qtr.		vs
	$		$		2nd Qtr			$		$		2nd Qtr			$		$		2nd Qtr

*Prescription Pharm:*		*2,520*		*2,230*		13	%		*771*		*718*		7	%		*1,749*		*1,512*		16	%
Remicade		394		307		28	%		—		—		—			394		307		28	%
Nasonex		295		242		22	%		175		144		22	%		120		98		22	%
Clarinex / Aerius		250		226		11	%		106		97		9	%		144		129		12	%
PegIntron		234		226		3	%		46		57		(19	%)		188		169		11	%
Temodar		216		171		26	%		79		72		10	%		137		99		38	%
Claritin Rx		102		104		(1	%)		—		—		—			102		104		(1	%)
Integrilin		78		82		(5	%)		73		78		(6	%)		5		4		8	%
Avelox		75		58		30	%		75		58		30	%		—		—		—
Rebetol		74		86		(14	%)		1		2		(56	%)		73		84		(13	%)
Caelyx		65		53		23	%		—		—		—			65		53		23	%
Proventil / Albuterol cfc		61		63		(4	%)		61		63		(4	%)		—		—		—
Intron A		55		64		(13	%)		28		33		(15	%)		27		31		(12	%)
Subutex / Suboxone		52		53		(2	%)		—		—		—			52		53		(2	%)
Elocon		43		38		12	%		—		1		N/M			43		37		16	%
Asmanex		42		20		108	%		39		18		119	%		3		2		16	%
Foradil		26		23		10	%		25		22		10	%		1		1		—
Noxafil		20		3		N/M			7		—		N/M			13		3		N/M

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 4

SCHERING-PLOUGH CORPORATION
GLOBAL PRESCRIPTION PHARMACEUTICAL SALES — KEY PRODUCT NET SALES
(Dollars in Millions)


	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.

*Global Prescription Pharm:*		*2,398*		*2,520*				*4,918*			*2,032*		*2,230*		*2,087*		*2,211*		*4,263*		*8,561*		13	%		15	%

Remicade		373		394				767			278		307		317		337		585		1,240		28	%		31	%
Nasonex		284		295				579			229		242		221		253		471		944		22	%		23	%
Clarinex / Aerius		204		250				455			160		226		171		164		386		722		11	%		18	%
PegIntron		217		234				451			196		226		206		208		423		837		3	%		7	%
Temodar		196		216				412			163		171		179		189		334		703		26	%		23	%
Claritin Rx		112		102				214			101		104		74		78		205		356		(1	%)		5	%
Integrilin		84		78				163			80		82		82		85		162		329		(5	%)		—
Avelox		115		75				191			80		58		63		103		138		304		30	%		38	%
Rebetol		71		74				146			78		86		72		75		164		311		(14	%)		(11	%)
Caelyx		62		65				127			51		53		52		49		104		206		23	%		22	%
Proventil / Albuterol Cfc		53		61				114			41		63		45		55		104		203		(4	%)		10	%
Intron A		60		55				115			60		64		57		57		124		237		(13	%)		(7	%)
Subutex / Suboxone		56		52				108			48		53		51		51		101		203		(2	%)		7	%
Elocon		36		43				79			34		38		36		33		72		141		12	%		8	%
Asmanex		43		42				85			20		20		28		36		40		103		108	%		112	%
Foradil		26		26				52			21		23		22		28		44		94		10	%		17	%
Noxafil		16		20				36			2		3		6		10		4		19		N/M			N/M

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 5

SCHERING-PLOUGH CORPORATION
U.S. PHARMACEUTICAL SALES — KEY PRODUCT NET SALES
(Dollars in Millions)


	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.

*Total U.S. Pharm:*		*802*		*771*				*1,573*			*656*		*718*		*733*		*800*		*1,375*		*2,908*		7	%		14	%
Nasonex		177		175				352			144		144		153		171		288		611		22	%		22	%
Clarinex / Aerius		91		106				197			70		97		98		94		167		358		9	%		18	%
PegIntron		49		46				95			43		57		51		49		100		201		(19	%)		(5	%)
Temodar		74		79				154			67		72		72		74		140		286		10	%		10	%
Integrilin		80		73				153			76		78		78		81		154		312		(6	%)		—
Avelox		115		75				191			80		58		63		103		138		304		30	%		38	%
Proventil / Albuterol Cfc		53		61				114			41		63		45		55		104		203		(4	%)		10	%
Intron A		31		28				59			30		33		28		29		63		120		(15	%)		(5	%)
Elocon		—		—				—			—		1		1		1		2		3		N/M			N/M
Asmanex		40		39				80			18		18		26		33		36		94		119	%		123	%
Foradil		25		25				50			20		22		22		27		42		91		10	%		18	%
Noxafil		6		7				13			—		—		2		3		—		4		N/M			N/M

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 6

SCHERING-PLOUGH CORPORATION
INTERNATIONAL PHARMACEUTICAL SALES — KEY PRODUCT NET SALES
(Dollars in Millions)


	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.

*Total International Pharm:*		*1,596*		*1,749*				*3,345*			*1,376*		*1,512*		*1,354*		*1,411*		*2,888*		*5,653*		16	%		16	%
Remicade		373		394				767			278		307		317		337		585		1,240		28	%		31	%
Nasonex		107		120				227			85		98		68		82		183		333		22	%		24	%
Clarinex / Aerius		113		144				258			90		129		73		70		219		364		12	%		18	%
PegIntron		168		188				356			153		169		155		159		323		636		11	%		10	%
Temodar		122		137				258			96		99		107		115		194		417		38	%		33	%
Claritin Rx		112		102				214			101		104		74		78		205		356		(1	%)		5	%
Integrilin		4		5				10			4		4		4		4		8		17		8	%		11	%
Rebetol		71		73				144			76		84		72		73		161		306		(13	%)		(10	%)
Caelyx		62		65				127			51		53		52		49		104		206		23	%		22	%
Intron A		29		27				56			30		31		29		28		61		117		(12	%)		(8	%)
Subutex / Suboxone		56		52				108			48		53		51		51		101		203		(2	%)		7	%
Elocon		36		43				79			34		37		35		32		70		138		16	%		12	%
Asmanex		3		3				5			2		2		2		3		4		9		16	%		19	%
Noxafil		10		13				23			2		3		4		7		4		15		N/M			N/M

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 7

SCHERING-PLOUGH CORPORATION
GLOBAL CONSUMER HEALTH CARE
NET SALES ANALYSIS
(Dollars in Millions)


	2007									2006
	1st		2nd		3rd	4th	6		Full	1st		2nd		3rd		4th		6		Full		2nd Qtr			6 Mos.
	Qtr.		Qtr.		Qtr.	Qtr.	Mos.		Year	Qtr.		Qtr.		Qtr.		Qtr.		Mos.		Year		vs			vs
	$		$		$	$	$		$	$		$		$		$		$		$		2nd Qtr			6 Mos.

*Consumer Health Care:*		*345*		*394*				*739*			*311*		*349*		*259*		*205*		*659*		*1,123*		13	%		12	%

OTC:		177		182				359			153		149		138		118		302		558		22	%		19	%
OTC Claritin		127		137				264			111		111		95		72		222		390		23	%		19	%
Other OTC		50		45				95			42		38		43		46		80		168		20	%		19	%
Foot Care		78		102				180			83		96		92		73		179		343		7	%		1	%
Sun Care		90		110				200			75		104		29		14		178		222		6	%		12	%

All figures rounded. Totals may not add due to rounding. Percentages based on unrounded figures.

Page 8

SCHERING-PLOUGH CORPORATION
CONSOLIDATED OPERATIONS DATA
(Dollars in Millions)
(Unaudited)


	2007												2006
	1st			2nd			3rd	4th	6			Full	1st			2nd			3rd			4th			6			Full
	Qtr.			Qtr.			Qtr.	Qtr.	Mos.			Year	Qtr.			Qtr.			Qtr.			Qtr.			Mos.			Year
	$			$			$	$	$			$	$			$			$			$			$			$

Geographic net sales
U.S.		1,179			1,195					2,374				999			1,103			1,047			1,043			2,102			4,192
Europe and Canada		1,215			1,343					2,558				1,046			1,206			1,044			1,107			2,252			4,403
Latin America		311			327					638				260			248			233			249			508			990
Asia Pacific		270			313					583				246			261			250			251			507			1,009

Consolidated net sales		2,975			3,178					6,153				2,551			2,818			2,574			2,650			5,369			10,594


	2007												2006
	1st			2nd			3rd	4th	6			Full	1st			2nd			3rd			4th			6			Full
	Qtr.			Qtr.			Qtr.	Qtr.	Mos.			Year	Qtr.			Qtr.			Qtr.			Qtr.			Mos.			Year
	$			$			$	$	$			$	$			$			$			$			$			$

Other income, net
Interest income		(82	)		(86	)				(167	)			(68	)		(69	)		(77	)		(83	)		(137	)		(297	)
Interest expense		37			39					76				46			45			40			41			91			172

(Gain)/loss on fair value of foreign currency option		(3	)		35					31				—			—			—			—						—
Foreign exchange (gains)/losses		—			(3	)				(2	)			—			5			—			(4	)		6			2
Other (income)/expense		—			(1	)				—				(12	)		—			—			—			(12	)		(12	)


Total — Other income, net		(48	)		(16	)				(62	)			(34	)		(19	)		(37	)		(46	)		(52	)		(135	)

All figures rounded. Totals may not add due to rounding.


		Alex Kelly		908-298-7450

		Robyn Brown		908-298-7417

Page 9